AKEBIA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
AKEBIA THERAPEUTICS, INC. (AKBA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $4.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-02-26
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $4.30M, a 16.22% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $3.70M, a 42.19% decline from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $6.40M, a 23.81% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $8.40M, a 20.75% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2025-12-31 | $4.30M 10-K · filed 2026-02-26 |
| 2024-12-31 | $3.70M 10-K · filed 2026-02-26 |
| 2023-12-31 | $6.40M 10-K · filed 2026-02-26 |
| 2022-12-31 | $8.40M 10-K · filed 2024-03-14 |
| 2021-12-31 | $10.60M 10-K/A · filed 2023-08-28 |
| 2020-12-31 | $6.80M 10-K/A · filed 2023-08-28 |
| 2019-12-31 | $4.30M 10-K · filed 2022-03-01 |
| 2018-12-31 | $13.60M 10-K · filed 2021-02-25 |
| 2017-12-31 | $5.60M 10-K · filed 2020-03-12 |
| 2016-12-31 | $4.60M 10-K · filed 2019-03-26 |
| 2015-12-31 | $3.20M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |